ClinicaliQ Trial Snapshot
- Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE) — Recruiting • Oncology • NCT06153667.
- What is being tested: Safety and performance of Bearing nsPVA (non-spherical polyvinyl alcohol) embolization particles as an embolic agent for uterine artery embolization in patients undergoing treatment for uterine fibroids, with follow-up data collected over 6 months.
- Patient eligibility overview: The study includes subjects who have been selected for and are undergoing uterine fibroid embolization treatment; specific inclusion/exclusion criteria would be defined in the full protocol but generally encompasses patients with symptomatic fibroids suitable for this minimally invasive vascular….
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.
Eligibility Snapshot
- : * Adult women ≥ 18 years old at the time of enrollment. * Subject has symptomatic uterine fibroid(s), suitable to embolization. * Subject provides written informed consent.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.